¸é¿ª°ü¹®¾ïÁ¦Á¦ ¼¼°è ½ÃÀåÀº 2023³â 474¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2032³â±îÁö 16.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
ÀÌ·¯ÇÑ ¼ºÀåÀ» °ßÀÎÇÏ´Â °ÍÀº Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡¿Í °íµµÀÇ ¸ÂÃãÈµÈ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿äÀÔ´Ï´Ù. ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï´Â ¸é¿ªÃ¼°èÀÇ ´É·ÂÀ» °ÈÇÏ¿© Èæ»öÁ¾, Æó¾Ï, ½Å¼¼Æ÷¾Ï µî¿¡ È¿°ú¸¦ ³ªÅ¸³À´Ï´Ù. ±¤¹üÀ§ÇÑ ÀÓ»ó½ÃÇè, ¿ì¼öÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ÀÇ ÅëÇÕÀÌ ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Á¾¾çÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í °·ÂÇÑ ½Å±Ô ¾ïÁ¦Á¦ ÆÄÀÌÇÁ¶óÀÎÀÌ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 7¿ù ·©Å² Á¤ºÎ´Â ¸é¿ª°ü¹®¾ïÁ¦Á¦¸¦ Æ÷ÇÔÇÑ ¾Ï Ä¡·á¿¡ 1,800¸¸ ´Þ·¯¸¦ ÅõÀÚÇßÀ¸¸ç, 2023³â ¾Ï ¿¬±¸¼Ò´Â ¾Ï ¸é¿ªÄ¡·á ¿¬±¸¿¡ 2,800¸¸ ´Þ·¯¸¦ ¹èÁ¤Çß½À´Ï´Ù. ÀÌ·¯ÇÑ Á¤ºÎ ¹× ±â°üÀÇ Áö¿øÀº ½ÃÀå ¼ºÀå¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.
¸é¿ª°ü¹®¾ïÁ¦Á¦´Â üũÆ÷ÀÎÆ®·Î ¾Ë·ÁÁø ´Ü¹éÁúÀ» Â÷´ÜÇÏ¿© ¾Ï¼¼Æ÷¸¦ °ø°ÝÇÏ´Â ¸é¿ª¼¼Æ÷ÀÇ ´É·ÂÀ» Çâ»ó½Ãŵ´Ï´Ù. ½ÃÀåÀº PD-L1, CTLA-4, PD-1, ±âŸ µî À¯Çüº°·Î ºÐ·ùµÇ¸ç, 2023³â¿¡´Â PD-1 ºÎ¹®ÀÌ 347¾ï ´Þ·¯ ±Ô¸ð·Î ¿ìÀ§¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ïº¼·ç¸¿°ú Æèºê·Ñ¸®ÁÖ¸¿°ú °°Àº PD-1 ¾ïÁ¦Á¦´Â ºñ¼Ò¼¼Æ÷Æó¾Ï, Èæ»öÁ¾, ½Å¼¼Æ÷¾Ï µî ´Ù¾çÇÑ ¾Ï¿¡¼ ³î¶ó¿î È¿°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. źźÇÑ ÀÓ»óÀû ¼º°ú¿Í Á¾¾çÇÐ ºÐ¾ß¿¡¼ÀÇ Ã¤Åà Ȯ´ë´Â PD-1 ¾ïÁ¦Á¦ ½ÃÀå¿¡¼ÀÇ ¼±µµÀû ÁöÀ§¸¦ ´õ¿í °È½Ã۰í ÀÖ½À´Ï´Ù.
¿ëµµº°·Î´Â Èæ»öÁ¾, À¯¹æ¾Ï, Æó¾Ï, ¹æ±¤¾Ï, È£ÁöŲ ¸²ÇÁÁ¾, ÀڱðæºÎ¾Ï, ´ëÀå¾Ï, ±âŸ·Î ±¸ºÐµÇ¸ç, 2023³â¿¡´Â Æó¾ÏÀÌ 25.1%ÀÇ Á¡À¯À²·Î ¼±µÎ¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2023³â ¹Ì±¹¿¡¼ Æó¾ÏÀ¸·Î Áø´Ü¹ÞÀº ȯÀÚ´Â 238,340¸í, »ç¸ÁÀÚ´Â ¾à 127,070¸íÀ̸ç, PD-1, PD-L1, CTLA-4¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(PD-1, PD-L1, CTLA-4)°ú ºñ¼Ò¼¼Æ÷Æó¾Ï(NSCLC) Ä¡·á¿¡ ¼º°øÀûÀ̶ó´Â Æò°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸¿Í ÀÓ»ó½ÃÇèÀº Æó¾ÏÀÇ ´Ù¾çÇÑ ´Ü°è¿¡¼ ÀÌ·¯ÇÑ ¾ïÁ¦Á¦ÀÇ Àû¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.
2023³â ºÏ¹Ì´Â 229¾ï ´Þ·¯ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2032³â±îÁö 16.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç¿Í ¾çÈ£ÇÑ ±ÔÁ¦ »óȲÀÌ ºÏ¹Ì ½ÃÀåÀ» °ÈÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ¾Ï Çùȸ´Â 2024³â ¹Ì±¹°ú ij³ª´Ù¿¡¼ ¾à 217¸¸ 450¸íÀÇ ½Å±Ô ¾Ï ȯÀÚ°¡ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, À̴ ÷´Ü ¾Ï Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù. ¶ÇÇÑ, ¾Ï ¿¬±¸ ¹× Ä¡·á¿¡ ´ëÇÑ Á¤ºÎ º¸Á¶±Ý Áõ°¡´Â ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
The Global Immune Checkpoint Inhibitors Market reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032. This growth is driven by the rising global cancer prevalence and demand for advanced, personalized therapies. Immune checkpoint inhibitors enhance the immune system's ability to target cancer cells, showing effectiveness against melanoma, lung cancer, and renal cell carcinoma. Extensive clinical trials, favorable regulatory approvals, and integration into treatment protocols support market expansion. Increased investments in oncology research and a strong pipeline of new inhibitors sustain market growth. For instance, in July 2021, the Rankin government invested USD 18 million in cancer therapies, including immune checkpoint inhibitors. In 2023, the Cancer Research Institute allocated USD 28 million for cancer immunotherapy research. Such support from governmental and organizational entities is crucial for market growth.
The overall immune checkpoint inhibitors industry is classified based on the type, application, end-use, and region.
Immune checkpoint inhibitors block proteins known as checkpoints, enhancing immune cells' ability to attack cancer cells. The market is categorized by type: PD-L1, CTLA-4, PD-1, and others. The PD-1 segment dominated in 2023 with USD 34.7 billion. PD-1 inhibitors, like nivolumab and pembrolizumab, show impressive efficacy across various cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. Robust clinical outcomes and growing adoption within oncology practices reinforce the leading market position of PD-1 inhibitors.
The market is segmented by application into melanoma, breast cancer, lung cancer, bladder cancer, Hodgkin lymphoma, cervical cancer, colorectal cancer, and others. In 2023, lung cancer led with a 25.1% share. Lung cancer's significant burden and the proven efficacy of these therapies enhance patient outcomes. In 2023, the U.S. saw 238,340 new lung cancer diagnoses, with approximately 127,070 fatalities. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have shown success in treating non-small cell lung cancer (NSCLC). Ongoing research and clinical trials are broadening the application of these inhibitors across various lung cancer stages.
In 2023, North America held a USD 22.9 billion share of the market, with a projected CAGR of 16.8% from 2024 to 2032. The presence of leading pharmaceutical companies and a favorable regulatory landscape bolster the North American market. The American Cancer Society estimates around 2,170,450 new cancer cases in the U.S. and Canada in 2024, highlighting the demand for advanced cancer therapies. Additionally, increasing government funding for cancer research and treatment is further driving the market's growth in the region.